Glenn Corbin
Optometrist · Wyomissing, PANPI 1508828666
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Maculogix, Inc. accounts for 77.7% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2021 at $18,500 and has fallen 94.8% since, to $963 in 2025. Among optometrist clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 213 payments — averaging $218.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Maculogix, Inc.$36K
- Alcon$4K
- Coopervision Inc.$1K
- Notal Vision, Inc.$700
- AbbVie$659
- Bausch & Lomb Americas Inc.$451
- plus $3K from 22 others
Across 444 payments — averaging $854.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$363K
- Shire North American Group Inc$13K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
What the payments were for
- Consulting fees$25,24554%
- Speaking & faculty fees$11,37124%
- Travel & lodging$5831%
- Food & beverage$9,42420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Maculogix, Inc. | 19 | $36,222 |
| Alcon | 36 | $4,078 |
| Coopervision Inc. | 32 | $1,078 |
| Notal Vision, Inc. | 1 | $700 |
| AbbVie(2 entities) | 22 | $659 |
| Bausch & Lomb Americas Inc. | 17 | $451 |
| Sun Pharmaceutical Industries Inc. | 15 | $367 |
| LKC Technologies, Inc. | 4 | $345 |
| Tarsus Pharmaceuticals, Inc. | 6 | $284 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $276 |
| Shire North American Group Inc | 5 | $232 |
| Oyster Point Pharma, Inc. | 8 | $219 |
| Rxsight Inc | 3 | $207 |
| Dompe US, Inc. | 3 | $177 |
| Glaukos Corporation | 2 | $156 |
| Novartis | 8 | $151 |
| Astellas Pharma Global Development | 1 | $150 |
| Amgen | 2 | $143 |
| Biotissue Holdings Inc. | 6 | $119 |
| Alcon Research LLC | 2 | $111 |
| Apellis Pharmaceuticals, Inc. | 1 | $110 |
| Ortho-clinical Diagnostics, Inc. | 1 | $101 |
| Johnson & Johnson Vision Care, Inc. | 3 | $84 |
| Quidel Corporation | 2 | $57 |
| Kala Pharmaceuticals, Inc. | 3 | $57 |
| ABB Con-cise Optical Group LLC | 1 | $35 |
| Astellas Pharma US Inc | 1 | $35 |
| Harrow Eye, LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AdaptDx$36,066
- Pataday$1,680
- DAILIES$321
- XIIDRA$244
- Izervay$150
- TOTAL30$150
- DAILIES TOTAL1$150
- Precision 1$150
- KXL System$128
- Photrexa$128
- TEPEZZA$125
- CEQUA$125
- Oxervate$124
- MIEBO$120
- RXSIGHT CONTACT LENS$119
- RXSIGHT INJECTOR HANDPIECE$119
- RXSIGHT INJECTOR CARTRIDGE$119
- LIGHT ADJUSTABLE LENS (LAL)$119
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$119
- MyDay Contact Lens$111
How this compares
$46,624 in reported general payments places this provider in the 95th percentile of 2,165 optometrist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 29 | $34,950 |
| XiidraLifitegrast | 15 | $29,600 |
| XdemvyLotilaner | 11 | $20,050 |
| LumiganBimatoprost | 31 | $18,440 |
| Cyclosporine | 21 | $17,804 |
| MieboPerfluorohexyloctane/Pf | 17 | $12,624 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 15 | $3,021 |
| Doxycycline Hyclate | 11 | $2,007 |
| Brimonidine Tartrate | 11 | $1,598 |
| Latanoprost | 74 | $997 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 30 | $344 |
| Timolol Maleate | 25 | $228 |
| Dorzolamide Hcl | 23 | $215 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $659 | $53,39060 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $451 | $42,22432 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $284 | $20,05011 claims |
| AlconSimbrinza | $4,078 | $3,02115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,165 optometrist providers in Pennsylvania.
Other optometrist in Wyomissing
- Amanda LeggeWyomissing$35K
- James DeomHazle Township$793K
- Gregory CaldwellDuncansville$547K
- Leslie O DellNew Freedom$388K
- Kevin BistlinePlymouth Meeting$302K
- Thomas KislanStroudsburg$266K
- Erick HendersonPittsburgh$266K
- Ryan YealyLancaster$164K
- Joseph SmayNew Kensington$147K
- Julie McLaughlinAllentown$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.